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Endothelium-derived nitric oxide plays a critical role in the
modulation of the contractile activity of vascular smooth
muscle and, therefore, in the regulation of vascular tone by
the endothelium (1) . Nitric oxide is synthesized by endothe-
lial cells from the amino acid L-arginine (2) and causes
vascular relaxation through activation of smooth muscle
guanylate cyclase .
Previous investigations have identified impaired endothe-
lium-dependent vascular responses in hypercholesterolemia
(3-6), even in the absence of overt atherosclerosis (7-13) .
We have recently shown that this impairment is largely
related to a defect in the endothelium-derived nitric oxide
From the Cardiology Branch, National Heart, Lung, and Blood Institute,
National Institutes of Health, Bethesda, Maryland .
Manuscript received June 17, 1993 ; revised manuscript received October
26, 1993, accepted November 1, 1993 .
Address for corresrmndenc4 : Dr. Julio A . Panza, National Institutes of
Health, Building 10, Room 7B-15, Bethesda, Maryland 20892 .
(01994 by
the American College of Cardiology
JACC Vol . 23, No. 4
March 15, 1994:944-50
Conclusions . The augmentation of endothelium-dependent
v tion by
L- inine, the nitric oxide precursor, is defective
in by terol is patients. This sup the concept of an
abnormal e otheilu -derived nitric oxide system in by rcho .
erole and indicates that decre availability of nitric
oxide substrate is not responsible for the impaired endothelial
function in this condition .
(J Am Coil C iol 1994,23 .844-50)
system (14) . However, the precise mechanism underlying
this abnormality is not known.
It has been reported in both animal (15-18) and hu-
man (19,20) studies that infusion of L-arginine improves
endothelium-dependent vasodilation in hypercholesterol-
emia, thus suggesting that decreased availability of the
substrate for nitric oxide might be responsible for the im-
paired vascular responses observed in this condition . How-
ever, other studies have shown that L-arginine may signifi-
cantly potentiate endothelium-dependent vasodilation in the
fore of normal humans (21,22) . Moreover, o-arginine, an
optically different isomer of arginine that is not a precursor
for nitric oxide production, has also been shown to produce
vasodilation (23) and to augment endothelium-dependent
responses (22), especially at high doses . These observations
bear particular relevance with regard to the implications of
the effect of L-arginine on endothelial function in hyper-
cholesterolemia.
The purpose of the present investigation was to determine
whether the abnormal endothelium-dependent vascular re-
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taxation observed in patients with hypercholesterolemia is
related to decreased availability of substrate for nitric oxide
production . We hypothesized that if reduced availability of
nitric oxide substrate was the cause of endothelial dysfunc-
tion, then administration of L-arginine should produce an
exaggerated effect on endothelium-dependent vasodilation
in hypercholesterolemic patients compared with normal
subjects .
Methods
Study patients. Twelve patients with hypercholesterol-
emia without any other apparent medical condition were
enrolled in the study . Each subject was screened by clinical
history, physical examination, routine chemical analyses,
electrocardiography and chest radiography . Patients were
included in the study if the plaswv . kholesterol level, mea-
sured at the time of initial screening after a 12-h fasting
period, was >240 mg/dl and if they had no history or
evidence of present or past hypertension, cardiac disease,
diabetes
mellitus,
peripheral vascular disease, coagulopathy
or any other disease predisposing them to vasculitis or
Raynaud phenomenon . There were six men and six women
with a mean age of 52 ± 9 years (range 39 to 71). Eleven of
the 12 patients had never been treated with antihyperlipi-
demic drugs . The remaining patient was instructed to dis-
continue her medication (lovastatin) 6 weeks before the
study. During this period, her cholesterol level increased
from 253 to 366 mg/dI .
A group of 15 normal volunteers (8 men, 7 women),
matched with the patients for approximate age, was selected
as a control group. Their mean age was 50 ± 6 years (range
41 to 64). Each subject underwent a screening identical to
that described for the hypercholesterolemic patients and had
no evidence of present or past hyperlipidemia (plasma cho-
lesterol was 010 mg/dl), hypertension, cardiac disease or
any other systemic condition . None of these subjects was
taking any medication at the time of the study .
None of the 12 hypercholesterolemic patients and 3 of the
15 normal control subjects were smokers (>10 cigarettes/
day) at the time of the study . The latter three subjects were
asked to refrain from smoking for 24 h before the study . In
addition, three patients and two control subjects had a
history of smoking in the past . All participants gave written
informed consent for all procedures . This study was ap-
proved by the National Institutes of health Investigational
Review Board .
Lipid measurements. Initial screening for 12-h fasting
plasma cholesterol levels was performed in all participants
with the enzymatic cholesterol oxidase and esterase tech-
nique (Boehringer Mannheim Diagnostics) . In addition, on a
separate day, blood samples were obtained after a 12-h fast
for measurement of a lipid profile by using the Allain Method
on the Abbott VP Super System auto analyzer with Abbot
reagents and Boehringer Mannheim standards (Abbott Labs
Diagnostics) . This profile included measurements of total,
high density lipoprotein, low density lipoprotein and very
low density lipoprotein cholesterol and triglycerides .
Protocol . All studies were performed in the morning in a
quiet room with a temperature of approximately 22°C (72 0F),
Participants were asked to refrain from drinking alcohol or
beverages containing caffeine and from smoking for at least
24 h before their studies .
Each study consisted of infusion of drugs into the brachial
artery and measurement of the response of the vasculature
(changes in regional blood flow) by means of forearm pleth-
ysmography . While the participants were supine, a needle
was inserted into the left brachial artery . This arm was
slightly elevated above the level of the right atrium, and a
mercury-filled Silastic strain gauge was placed on the widest
part of the forearm (24,25) . The strain gauge was connected
to a plethysmograph (model EC-4, D.E. Hokanson) (26)
calibrated to measure the percent change in volume . The
plethysmograph in turn was connected to a chart recorder to
record the forearm blood flow measurements . For each
measurement, a cuff placed on the upper arm was inflated to
40 mm Hg with a rapid cuff inflator (model E-10, D .E .
Hokanson) to occlude venous outflow from the extremity . A
wrist cuff was inflated to suprasystolic pressures I min
before each measurement to exclude the hand circulation
(27) . Flow measurements were recorded for approximately
7 s every 15 s . Seven readings were obtained for each mean
value .
Basal measurements were obtained after a 3-min infusion
of 5% dextrose solution at I ml/min . Forearm blood flow was
then measured after the infusion of acetylcholine and sodin .n
nitroprusside. Acetylcholine was used as an endothelium-
dependent agent that induces vasodilation by stimulating the
release of relaxing factors from the vascular endothelium
(28,29) . Sodium nitroprusside was used as an endothelium-
independent substance because its vasodilator effect is
largely due to its direct action on smooth muscle cells
(30,31) .
Acetylcholine chloride (Sigma Chemical) was infused at
7.5, 15 and 30 pgtin and sodium nitroprusside at 0 .8, 1 .6
and 3.2 rg/min (infusion rates 0.25, 0.5 and I mllmin,
respectively, for each drug) . Each dose was infused for
5 min, and forearm blood flow was measured during the last
2 min of each infusion . A 30-man rest period was allowed,
and basal measurements were repeated between the infusion
of the two drugs .
After another 30-min rest period, blood flow measure-
ments were obtained to corroborate return to basal values .
Then, L-arginine was infused at 40 umol/min (infusion rate
I ml/min) for 5 min, and forearm blood flow was measured
during the last 2 min of the infusion . Subsequently, cumula-
tive dose-response curves for acetylcholine and sodium
nitroprusside were repeated using the same doses, infusion
rates and rest interval mentioned previously . The infusion of
L-arginine was maintained during the performance of these
repeated dose-response curves . L-arginine was then discon-
tinued during the rest period but was reinstated before
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obtaining the second of these curves . The sequence of
administration of acetylcholine and sodium nitroprusside,
both before and after infusion of L-arginine, was randomized
to avoid any bias related to the order of drug infusion .
In the 12 hypercholesterolemic patients and in I I normal
control subjects, D-arginine was subsequently infused into
the brachial artery at 40 pmoltmin (infusion rate I ml/min),
and another cumulative dose-response curve for acetylcho-
line was obtained using the doses previously mentioned .
D-Arginine is an optically different form of arginine that is
not incorporated into proteins and is not a substrate for
endothelial synthesis of nitric oxide . D-Arginine, therefore,
was utilized to determine whether the effect of L- "nine on
basal vascular tone and on the response to acetylcholine was
due to the latter's property of being the natural nitric oxide
precursor (32) . o-Arginine was supplied by Sigma Chemical .
The product was prepared by the Pharmaceutical Develop-
mental Service of the National Institutes of Health to ensure
sterility of the solution . In addition, high performance liquid
chromatography or ultraviolet light assay was used to ascer-
tain its purity .
During the study, the participants did not know which
drug was being infused. All blood pressures were recorded
directly from the intraarterial catheter immediately before
each measurement. Forearm vascular resistance was calcu-
lated as the mean arterial pressure divided by the forearm
blood flow .
SUAWJW walysis.
Differences between two mean values
were compared by paired or unpaired Student t test, as
appropriate . The responses to sodium nitroprusside and
acetylcholine were compared by analysis of variance for
repeated measures using a multiple linear regression model
that included dummy variables to correct for between-
subjects variability (33) . All calculated p values are two
tailed. All p values < 0.05 were considered significant . All
group data are reported as mean value ± SD, unless other-
wise indicated.
Results
Characteristics of stady patients . By selection, the plasma
cholesterol levels at the time of screening were significantly
higher in the hypercholesterolemic patients than in the
normal control subjects (285 ± 35 vs. 171 ± 32 mg/dI, p <
0.0001). The lipoprotein fractions subsequently measured on
a separate day in the hypercholesterolemic patients and
control subjects are shown in Table I .
Mean arterial blood pressure was similar in hypercholes-
terolemic patients and normal control subjects (86 ± 10 and
86 ± 9 mm Hg, respectively) . Basal foreann blood flow
(2.2 ± 0.8 and 2 .9 ± I ml/min per 100 ml, respectively) and
basal vascular resistance (37 .5 ± 16 and 32.1 ± 10 mm
Hg/ml-min-1-100 ml -1 , respectively) were also similar in
both groups
Table 1
. Plasma Lipoprotein Levels Measured in 12 Hyptickolesterolemic
Patients and 15 Normal Control
Subjects
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Values presented are mean value ± SD
. HDL = high density lipoprotein ;
LDL = low density lipoprotein ; VLDL = very low density lipoprotein.
Vascular response to acetylcholine and sodium nitroprus-
side. Acetylcholine produced a substantial vasodilator effect
in both patients and control subjects . However, the increase
in blood flow and decrease in vascular resistance in response
to acetylcholine were significantly attenuated in hypercho-
lesterolemic patients compared with normal control subjects
(Fig. 1). At the highest dose (30 4min), forearm blood flow
was 14 .4 ± 7 mUmin per 100 ml in the control subjects and
6.8 ± 4 ml/min per 100 ml in the hypercholesterolemic
patients (p < 0 .05).
No significant differences were found between the two
Figure 1 . Forearm blood flow and vascular resistance responses to
acetylcholine infusion in 15 normal control subjects (open circles)
and 12 hypercholesterolemic patients (solid circles) . Data represent
mean value and SEM : p value refers to the comparison of the two
curves by analysis of variance for repeated measures .
20 r O .-O Normal controls
0-6 Hypercholesterolemic patients
I
Hypercholesticiolemic
Patients
(mg/dl)
Normal
Control
Subjects (mgtd))
	
p Value
Total cholest-rol 268
± 44 189 ± 36 < 0 .0001
VLDL cholesterol
41 .3 ± 21 23 .6 ± 9 < 0 .021
LDL cholesterol 179 ± 33 119 ± 35
< 0.0001
HDL cholesterol
47 .9 ± 9 47 ± 14 0.85
Triglycerides 168 .7 ± 73 106 ± 43 < 0.02
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Figure 2 . Forearm blood flow and vascular resistance responses to
sodium nitroprusside infusion in 15 normal control subjects (open
circles) and 12 hypercholesterolemic patients (solid circles) . Data
represent mean value and SET p values as in Figure 1 .
groups in the forearm blood flow and vascular resistance
responses to sodium nitroprusside (Fig . 2) . At the highest
dose (3 .2 pg1min), forearm blood flow was 8 .8 4 ml/min
per 100 ml in the normal control subjects and 7 .1 3 ml/min
per 100 ml in the hypercholesterolemic patients .
Effect of L- and D-arginine on the vascular responses to
acetylcholine in normal subjects . The infusion of L- or o-
arginine did not change baseline blood flows or vascular
resistance in the normal control group . However, the vaso-
dilator response to acetylcholine was significantly increased
during the simultaneous infusion of L-arginine . At the high-
est dose of acetylcholine (30 p&Q, blood flow was 14 .4 ±
7 ml/min per 100 ml forearm volume before and 18 .9 ±
10 ml/min per 100 ml after infusion of L-arginine (p < 0 .002) .
In contrast, the vasodilator response to acetylcholine was
not significantly changed after infusion of D-arginine in I I
normal control subjects . Blood flow was 14.4 ± 7 ml/min per
100 ml before and 13 .4 ± 7 mUmm per 100 ml after infusion
of o-arginine (p = NS) . Therefore, when the effect of both L-
and D-arginine on the vascular responses to acetylcholine
were compared, it was evident that the increase in blood
flow was significantly greater during L-arginine infusion
(Fig. 3) .
Effect of L- and D-aFginine on the vascular responses to
acetylcholine in hypercholesterolemic patients . As in the con-
trol group, the infusion of either L- or o-arginine did not
change baseline blood flow or vascular resistance in the
hypercholesterolemic patients . In contrast to normal sub-
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Figure 3. Forearm blood flow and vascular resistance responses to
acetylcholine infusion in 15 normal control subjects after infusion of
L-arginine (solid circles) and D-arginine (open circles), Data represent
mean value and SEM ; p values as in Figure 1 .
jects, only a mild and not significant improvement was
observed in the vascular responses to acetylcholine with the
infusion of L-argick -,r - in the hypercholesterolemic patients .
At the maximal dose of acetylcholine, blood flow was 6 .8 ±
4 ml/min per 100 ml before and 8 .4 ± 5 mUmin per 100 ml
after infusion of L-arginine, respectively (p = 0 .16) . How-
ever, a mild but not significant change was also observed in
the vasodilator effect of acetylcholine with D-arginine . Blood
flow was 6 .8 ± 4 mUmin per 100 ml before and 8 .3 ± 4 ml/min
per 100 ml after infusion of o-arginine (p = 0 .07). Conse-
quently, when the effects of L- and D-arginine on the
vascular responses to acetylcholine were compared, no
difference was observed between the two curves (Fig . 4) .
Effect of L-arginine on the vascular responses to sodium
nitroprusside . The infusion of L-arginine did not modify the
vasodilator response to sodium nitroprusside in either nor-
mal control subject- (maximal flow 8 .8 ± 4 vs . 9.9 -±
6 ml/min per 100 ml before and after L-arginine infusion,
respectively) or in h yperc hole steroleMiL patients (maximal
blood flow 7 .1 ± 3 vs . 7 .1 ± 2 ml/An per 100 ml before and
after L-arginine infusion, respectively) .
Discussion
Present investigation . The purpose of this study was to
investigate the possibility that decreased availability of 1--
arginine, the natural substrate for the endothelial synthesis of
nitric oxide, was responsible for the impaired endothelium-
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Apire 4. Forearm blood flow and vascular resistance responses to
acetylcholine infusion in 12 hypercholesterolemic patients after
infusion of L-arginine (solld drcles) and n-arginine (open circles) .
Data represent mean value and SEM ; p values as in Figure 1 .
dependent vasodilation of patients with hypercholesterol-
emia. Previous studies from our laboratory and others have
shown that intraarterial administration of L-arginine aug-
ments endothelium-dependent responses in normal humans
(21,22). We therefore hypothesized that if the cause for the
impaired endothelium-mediated vasodilation in hypercholes-
terolemia was related to a deficiency of the substrate for
nitric oxide synthesis, then administration of L-arginine
should produce an exaggerated effect on the response to
acetylcholine in hypercholesterolemic patients . The results
of our study showed that patients with hypercholesterol'unnia
failed to exhibit the augmentation in the endothelium-
dependent vasodilator response to acetylcholine observed in
normal control subjects with administration of L-arginine .
Although r mild but not significant increase in the response
to acetylcholine with L-arginine was observed, such an effect
was not different from that measured with D-arginine, an
optically different form of arginine that is not a substrate for
nitric oxide synthesis (32) . This latter observation indicates
that the effect of L-arginine on endothelium-dependent va-
sodilation in the hypercholesterolemic patients was not due
to a specific action through the nitric oxide system but was
probably related to other mechanisms of vasodilation
(23,34-36). In conjunction, the present findings indicate that
the impaired vascular responses of hypercholesterolemic
patients are not a consequence of reduced availability of
endothelial cells to L-arginine, and therefore a different
defect must be responsible for this abnormality .
Previous studies, Our results differ from those of previ-
ous investigations related to the effect of L-arginine on
endothelium-dependent vasodilation in animal and human
models of hypercholesterolemia . Those studies showed that
izarginine may indeed improve and even normalize impaired
endothelium-mediated responses in hypercholesterolemia
(15-21). Several factors related to the methodology used in
the different studies may account for this discrepancy . First,
most animal studies focused on the effect of L-arginine on the
vascular responses of large conductance vessels (16-18),
whereas our results largely reflect the response of small
resistance arteries. It is therefore possible that diversity in
the specific behavior of each vascular bed is at least partly
responsible for the dissimilar results . This may also explain
the discordance between our findings and those of Drexler et
al . (19), who studied the effect of L-arginine on endothelium-
dependent responses of the coronary microcirculation (19) .
Second, whereas previous investigators studied the
response of atherosclerotic vessels to administration of L-
arginine (37), our findings -% related to the small resistance
vessels of the forearm, which are unlikely to undergo ath-
erosclerotic changes and may therefore have a different
mechanism of endothelial dysfunction .
Third, the discrepancy between our results and those of
Creager et al . (20), who also studied the effect of L-arginine
on endothelium-dependent responses of the forearm vascu .
!ature in hypercholesterolemic patients, may be related to
their use of intravenous administration of L-arginine . This
difference may have resulted in different intravascular con-
centrations uf the amino acid and, more important, may have
triggered systemic responses, such as the release of hista-
mine (34) or insulin (35,36), that interfered with the direct
vascular effects of the amino acid . In the study of Creager et
al. (20), the effect of L-arginine on endothelium-dependent
vasodilation with methacholine was largely observed at
higher levels of vasodilation than those achieved in our
patients with the maximal dose of acetylcholine . It is there-
fore possible that we might have observed an increase in
endothelium-dependent vasodilator responses had higher
doses of acetylcholine been used in our patients . However,
this is not relevant to the hypothesis we tested . If decreased
availability of nitric oxide substrate were the cause for the
impaired response to acetylcholine in hypercholesterolemia,
then administration of L-arginine should have produced a
measurable effect at least similar to that observed in normal
subjects at the doses of acetylcholine used in our study.
Our study patients were slightly older than those studied
by Creager et al . (20) (mean age 52 ± 9 vs . 39 ± 2 years) .
Because endothelium-dependent vasodilation worsens with
age (38), it is possible that our patients exhibited greater
endotheliall dysfunction, as further suggested by the fact that
the blood flow measured at the highest dose of acetylcholine
was 48% of the level in the control group in our study
patients as opposed to 72% of the control level in the patients
studied by Creager et al. (20). It is therefore reasonable to
speculate that milder forms of endothelial dysfunction are
JACC Vol . 23 . No . 4
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related to decreased availability of L-arginine and, as the
disease process progresses, other mechanisms responsible
for the more severe endothelial dysfunction overwhelm the
importance of the former phenomenon in the vascular patho-
physiology of hypercholesterolem ia .
Finally, our finding of potentiation of the forearm vascu-
lar response to acetylcholine with L-arginine in normal
control subjens, although in contrast to previous studies
using different routes of administration and testing different
vascular beds (15-20), is in agreement with those reported
recently by Imaizumi et al . (N), who also utilized intraarte-
rial infusion of drugs .
Study limitations. Certain aspects of our study design
may affect the interpretation of its results, First, although
based on known circulating levels of L-arginine (20,21), the
dose used in this study was sufficient to increase its intra-
vascular concentration severalfold, we cannot ascertain that
this actually resulted in increased intracellular levels be-
cause it is theoretically possible that the endothelial uptake
of i-arginine is reduced in hypercholesterolemia . However,
studies with dietary supplementation of L-arginine that dou-
bled its circulating levels resulted in improvement in endo-
thelial function in cholesterol-fed animals (37), suggesting
that the uptake of the amino acid by the vascular endothe
lium is not significantly impaired in hypercholesterolemia .
Second, although our results indicate that a deficiency of
the nitric oxide precursor is not the cause for impaired
endothelium-mediated vasodilation in hypercholesterolei -ftia,
the study design does not allow us to determine the precise
location of the endothelial abnormality that accounts for the
blunted response to acetylcholine, The defect may reside in
the endothelial cell muscarinic receptor, in the intracellular
signal transduction pathway that carries the message from
the membrane receptors to the enzyme that synthesizes
nitric oxide (39), in the enzyme itself or even in the break-
down of nitric oxide by superoxide anions within the endo-
thelial cell or in the interstitium (40) . However, our findings
of reduced effect of L-arginine on endothelium-dependent
vasodia6on do qopport the concept that a defect in the nitric
oxide system is at least partly responsible for the endothelial
dysfunction of hypercholesterolemia (14) .
Finally, our study was not designed to assess the useful-
ness of L-arginine administration to improve vascular func-
tion or to delay the development of atherosclerosis in
hypercholesterolemic patients . Therefore, our findings do
not negate the potential beneficial effects of L-arginine on the
progression of atherosclerosis suggested by recent animal
studies (38) . It is possible that administration of L-arginine
on a long-term basis may affect certain cellular phenomena
that participate in the atherosclerotic process, such as mono-
cyte adherence and platelet reactivity (38). However, this
does not constitute evidence for decreased endothelial avail-
ability of nitric oxide precursor in hypercholesterolemia, the
hypothesis tested in our study . Moreover, recent studies in
animal models of diet-induced hypercholesterolemia and
atherosclerosis have suggested that the endothelial synthesis
of nitric oxide may actually be increased (41,42), thus
indicating that a deficiency of nitric oxide substrate is
probably not the cause of impaired endothelium-dependent
responses in this condition .
Conclur,ons. Our investigation demonstrates that the
normal augmentation of endothelium-dependent vasodila-
tion by L-arginine is defective in hypercholesterolemic pa-
tients. These findings support the concept of an abnormal
endothelium-derived nitric oxide system in hypercholester-
olemia and indicate that decreased availability of the natural
precursor of nitric oxide is not responsible for impaired
endothelial function in patients with this condition .
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